

MEDICAL INTELLIGENCE



DRUG THERAPY

JOHN A. OATES, M.D., *Editor*ALASTAIR J.J. WOOD, M.D., *Associate Editor*

THE USE OF KETOCONAZOLE AS AN INHIBITOR OF STEROID PRODUCTION

NICOLETTA SONINO, M.D.

KETOCONAZOLE is an imidazole derivative that is chemically related to miconazole (Fig. 1). It is an oral antimycotic agent with broad-spectrum activity and low toxicity.¹⁻³ The drug is considered to represent an important innovation in the treatment of fungal disease and has been used extensively in clinical practice for the past five years. The development of gynecomastia in some patients treated for mycosis first led to the investigation of the drug's effect on the production of testosterone.^{4,5} Thereafter, ketoconazole was shown to be a potent inhibitor of gonadal and adrenal steroid synthesis in vitro and in vivo.⁵⁻¹⁰ The finding of its important endocrine effects has aroused a new interest in this agent.¹¹ Extensive studies have been carried out to elucidate its mechanism of action. In addition, there have been clinical trials to assess its therapeutic potential. Because ketoconazole acts as a steroid inhibitor with differential selectivity, it is a new therapeutic tool in the management of conditions in which it is beneficial to suppress gonadal or adrenal hormone production, such as prostate cancer and Cushing's syndrome, respectively.

MECHANISM OF ACTION

Ketoconazole inhibits the synthesis of ergosterol in fungi and of cholesterol in mammalian cells.^{12,13} In addition, it interferes with cytochrome P-450 enzyme systems in several organs — namely, the testis,⁵ ovary,⁶ adrenal gland,⁷ kidney,¹⁴ and liver.^{15,16} Like other imidazole drugs, it appears to interact with cytochrome P-450 at the heme iron site.^{17,18}

Steroidogenesis

The most sensitive site of action in humans appears to be the C₁₇₋₂₀ lyase (Fig. 2), explaining the greater suppressibility of testosterone secretion, as compared with cortisol secretion, in humans after a single dose of 200 or 400 mg.^{10,19} A similar finding has been reported

in male beagle dogs.²⁰ Inhibition of C₁₇₋₂₀ lyase has been demonstrated by an increase in ratios of precursor (17 α -hydroxyprogesterone or 17 α , 20 α -dihydroxyprogesterone or both) to product (androstenedione or testosterone) both in vivo^{19,20} and in vitro.^{18,21-23} All in vitro studies to test C₁₇₋₂₀ lyase have used testis preparations, but clinical data show that both gonadal and adrenal androgens decrease after ketoconazole administration,^{7,9,24,25} indicating interference with adrenal C₁₇₋₂₀ lyase as well; the extent of this inhibition has not been determined. Since there is evidence that 17 α -hydroxylase and C₁₇₋₂₀ lyase activities reside in a single enzyme, it is not surprising that ketoconazole inhibits 17 α -hydroxylase as well (Fig. 2).^{21-23,26}

Cholesterol side-chain-cleavage blockade by ketoconazole has been demonstrated in both testicular and adrenal tissue preparations.^{14,27,28} In vitro studies in rat testicular microsomes have shown that cholesterol side-chain cleavage has a higher sensitivity to ketoconazole than does C₁₇₋₂₀ lyase.²⁷ A species-dependent sensitivity may account for this finding. Adrenocortical steroid biosynthesis is also inhibited at the 11 β -hydroxylation^{14,29-31} and 18-hydroxylation steps.³¹ Ketoconazole is more potent in vitro than metyrapone in the inhibition of both 11 β -hydroxylase and cholesterol side-chain cleavage (Fig. 2).³¹

The effects of ketoconazole on estrogen synthesis have not been fully clarified. In contrast to in vitro findings that the agent inhibits rat ovarian^{6,32} and testicular³³ and human placental³⁴ aromatase, in vivo studies have shown that the estradiol:testosterone ratio is increased in men given ketoconazole.³⁵⁻³⁷ No data are available on estrogen levels in women during treatment. An inhibitory effect on oversecretion of estrogen by adrenal tumors has been reported.^{25,38}

It is of interest that much higher concentrations are required to affect cytochrome P-450-dependent enzymes in mammalian tissues than to inhibit fungal cytochrome P-450.^{18,21,28} This may explain why endocrine effects become evident in patients only at high doses. Concentrations 12 times higher than those sufficient for antifungal activity are needed to inhibit androgen synthesis in testis microsomes. Cholesterol side-chain cleavage in testes and adrenals and adrenal 11 β -hydroxylase are inhibited at even higher concentrations.³⁹

Steroid Transport and Action

In addition to a direct action on multiple enzyme systems in different steroidogenic glands, other mechanisms by which ketoconazole may produce endocrine effects have been described. A glucocorticoid antagonist activity, which acts by occupying glucocorticoid receptors, has been observed in cultured hepatoma cells.⁴⁰ Displacement of dihydrotestosterone and, to a greater extent, estradiol from sex-hormone-binding globulin by ketoconazole is observed in vitro at drug concentrations equivalent to those in patients receiving high therapeutic doses.⁴¹ Cortisol-binding to corticosteroid-binding globulin is not affected.⁴¹ In normal volunteers and in patients on a high-dose regimen,

From the Department of Biochemistry, State University of New York at Buffalo, Buffalo, N. Y., and the Institute of Medical Semiotics, University of Padua, Padua, Italy. Address reprint requests to Dr. Sonino at the Institute of Medical Semiotics, University of Padua, via Ospedale 105, 35100 Padua, Italy.




Figure 1. Structure of Ketoconazole.

a significant elevation of the estradiol:testosterone ratio (both total and free hormone) occurs,^{35,36} but the percentages of bound and free fractions of both hormones are not significantly altered; thus, the displacement of estradiol from its binding globulin is not relevant *in vivo*.^{8,35,36} The increased estradiol:testosterone ratio may be an important factor in the development of gynecomastia,⁴² a principal side effect of the drug.^{4,5,8,35}

Ketoconazole seems to have no direct effect at the pituitary level on the secretion of either adrenocorticotropin⁴³ or luteinizing hormone²⁶ in rat tissue studied *in vivo* and *in vitro*. This is in agreement with clinical findings, as discussed below.

PHARMACOLOGY

The hormonal changes produced by the administration of ketoconazole are dose-dependent and fully reversible,^{5,7,8,10,19,20,35,41,43} with recovery from steroidogenic blockade 8 to 16 hours after an oral dose.^{7,10} A considerable degree of variation in the bioavailability of the drug has been observed in pharmacokinetic studies.^{44,45}

In normal subjects given a single oral dose of 200 or 400 mg of ketoconazole, the peak serum concentrations occur at two hours and are 3 to 4 and 5 to 8 μg per milliliter, respectively.^{44,46-48} Higher serum levels are found in patients taking 800 to 1200 mg per day.^{8,49} At eight hours, the drug is still measurable in serum, but it is undetectable at 24 hours.^{35,46,47} Administration immediately after a meal results in lower serum levels than does administration during fasting.^{46,48,49} Gastric acidity is required for absorption, which may be impaired by achlorhydria or antacid medication.^{48,50}

Serum or plasma levels of ketoconazole have been determined by bioassay^{46,49,51} and by more sensitive high-performance liquid chromatographic methods.^{52,53} Even at high concentrations the drug does not interfere with hormone radioimmunoassays.^{5,10,35,41}

The serum clearance of the drug

has been found to be biphasic, with an initial half-life of 1 to 3.3 hours^{46,49} and a terminal half-life of 8 hours.^{48,51} Protein-binding studies have shown a high percentage of ketoconazole bound to plasma proteins, mainly albumin: 99 percent in human whole blood,⁴⁷ and 93 and 91 percent in human serum at serum concentrations of 50 and 25 μg per milliliter.⁵⁴ The drug is widely distributed in body fluids, with detectable concentrations in urine, saliva, sebum, and cerumen after a 200-mg oral dose.⁴⁷ In a patient receiving 400 mg per day, semen ketoconazole concentrations one and three hours after the dose were 0.9 and 0.25 μg per milliliter, indicating penetration into the genitourinary tract.⁴¹ One study found that after an 800-mg dose, ketoconazole was measurable in the cerebrospinal fluid.⁵⁵

Ketoconazole is extensively metabolized into inactive compounds, primarily by the liver.^{47,48} Metabolites and unchanged drug are excreted mostly in the feces, with very little excretion into the urine. Although renal impairment does not seem to cause accumulation of the drug, hepatic insufficiency is a contraindication to its use, since the agent is metabolized mainly by the liver and might worsen liver damage by producing a toxic effect.^{47,48}

In addition to its hepatotoxicity, ketoconazole's interference with some mixed-function oxidase systems in liver microsomes^{15,16,56} may have important non-endocrine clinical effects that result from alterations in the hepatic metabolism of the drug. Possible drug interactions, which are most likely due to interference with enzyme activities in liver microsomes, include potentiation of oral anticoagulants by ketoconazole,⁵⁷ markedly diminished serum concentrations of both rifampin and ketoconazole upon simultaneous administration of those agents,⁵⁸ a delay in the post-dose peak of ketoconazole concentration during long-term ad-




Figure 2. Main Pathways of Adrenal Steroidogenesis.

SCC denotes cholesterol side-chain cleavage. HSD hydroxysteroid dehydrogenase, OH hydroxylase, and OH D hydroxy dehydrogenase. Black bars indicate ketoconazole inhibition, and black-and-white bars metyrapone inhibition.

ministration of phenytoin,⁴⁹ accumulation of cyclosporine during ketoconazole therapy,⁴⁸ and inhibition of the disposition of methylprednisolone.⁵⁹

Side Effects

The most common side effects at the doses usually employed for fungal infection (200 to 400 mg per day) are gastrointestinal reactions; pruritus, and alterations in hepatic function.^{15,47,48,56,60-62} About 10 percent of patients have transient abnormalities in liver function,^{60,63} but the incidence of true hepatic injury seems to be very low (0.1 to 1.0 percent).^{47,48,60} Fatal hepatitis⁶⁴ and anaphylaxis⁶⁵ have also been reported. The mechanism of liver damage induced by ketoconazole is still unclear. It seems to involve an idiosyncratic type of reaction that does not depend on the daily dose or the duration of treatment. However, an immune hypersensitivity mechanism could not be excluded in some cases. Biochemical tests and assessment for clinical signs of liver dysfunction at periodic intervals (i.e., biweekly for the first two months and then monthly) are therefore advised. No increased incidence of hepatotoxicity has been reported in patients receiving prolonged high-dose treatment (800 to 1200 mg per day). In patients on a regimen of 200 to 400 mg per day, gynecomastia^{4,5} is very rare. At higher doses, endocrine effects, such as impairment of testicular function^{8,66} and adrenal insufficiency,⁶⁷⁻⁶⁹ may occur. It is because ketoconazole produces such effects that it has been used to treat clinical conditions that may benefit from inhibition of either gonadal or adrenal steroid production (see below).

INHIBITION OF ANDROGEN PRODUCTION

A substantial decrease in total and free testosterone and androstenedione levels occurs in normal men two hours after a single 200-mg dose of ketoconazole.^{5,19} Recovery from suppression begins at 8 hours and is complete by 24 hours. There is a compensatory increase in plasma luteinizing hormone and no change in cortisol levels, as compared with values in persons receiving placebo, suggesting that there is selective inhibition of C₁₇₋₂₀ lyase at low doses.¹⁹ In patients receiving high or repeated doses on a long-term basis, end-organ effects of diminished testosterone levels become apparent, with marked individual variations. Large differences in mean serum levels of both ketoconazole and testosterone are found among patients receiving the same dosage; yet, an inverse correlation between ketoconazole and testosterone concentrations is consistently observed.^{8,37,70,71} During prolonged treatment with 800 to 1200 mg per day in a single dose for progressive systemic fungal disease, testosterone levels are subnormal over 24 hours in some cases, resulting in reduced sperm counts (after four months), azoospermia, decreased libido, impotence, and gynecomastia.⁸ Functional hypogonadism appears to be reversible upon drug withdrawal.

Because of its marked effects on the androgen-gonadotropin feedback system in vivo, ketoconazole

has been advocated for use in a test of gonadotropin reserve in men.³⁷ Additional studies are required to verify its feasibility and clinical usefulness. In the first trial, nine normal men received four doses of ketoconazole (300, 600, 900, and 1200 mg per day); each dose was given for one week. The response to luteinizing hormone-releasing hormone was assessed before and after each week. Increases in luteinizing hormone and follicle-stimulating hormone were maximal after the dose of 900 mg per day. However, there was great variability among subjects in the levels of both gonadotropin and testosterone at each dose tested.³⁷

Therapeutic Use

The potent inhibitory action of ketoconazole on testosterone synthesis (Fig. 2) has been used with therapeutic benefit in the management of prostate cancer.⁷⁰⁻⁷⁴ The drug acts very quickly and has the advantage over other treatments currently employed of also decreasing adrenal androgen production.⁷²⁻⁷⁴ At divided doses of 400 mg every eight hours, which prevent androgen levels from returning to base line, castrate values are initially recorded. However, the rise in luteinizing hormone triggered by the fall in testosterone leads to a progressive increase in testosterone levels.⁷⁰⁻⁷² Nevertheless, striking clinical improvement is seen in many patients; serum levels of prostatic acid phosphatase decrease and considerable pain relief and regression of some lesions occurs, greatly reducing the need for analgesics.⁷¹⁻⁷⁴ Indeed, clinical improvement seems to be better than would be expected on the basis of testosterone levels over the long term. However, in addition to impotence and gynecomastia, severe gastrointestinal disturbances⁷⁵ and signs of adrenal insufficiency^{71,72} may occur, requiring dose reduction and glucocorticoid replacement, respectively. Further hormonal assessment during long-term treatment shows a consistent rise in progesterone, no changes in prolactin and estradiol, and an increased estradiol:testosterone ratio.^{35,70-72}

The proposal to use ketoconazole as a "sole treatment" for prostate cancer⁷² has been questioned because of several problems that have arisen in some studies: sustained reductions in testosterone levels cannot be maintained, large diurnal fluctuations in serum testosterone occur in most patients, and compliance with a high-dose regimen and strict eight-hour timing of doses is somewhat difficult to obtain.^{70,71,75} Nevertheless, good results are generally reported, especially in patients previously castrated or with castrate testosterone levels produced by administration of gonadotropin-releasing hormone analogues. In such patients, ketoconazole, by suppressing adrenal androgen output, brings about further objective or subjective remissions.^{71,75} Indeed, a rationale for combined treatment with ketoconazole and superactive analogues of gonadotropin-releasing hormone in this disease has been suggested by the more pronounced androgen suppression obtained with both drugs than with either alone, in studies in both humans^{75,76} and

imals.⁷⁷ Improvement has been reported in some patients in whom the combination drug treatment was introduced after other treatment methods had been used.⁷⁵ However, it has not been proved that the combined treatment is more effective than ketoconazole alone, and further evidence is needed before it can be recommended.

Successful therapy with ketoconazole for up to 12 months has been reported in three children (3.3 to 3.9 years old) with precocious puberty and autonomous Leydig-cell hyperactivity with low basal and gonadotropin-releasing hormone-stimulated gonadotropin levels.⁷⁸ Divided doses (up to 600 mg per day) were employed, with striking behavioral and clinical improvement. The growth rate and skeletal maturation were both reduced, and low levels of testosterone and adrenal androgens were maintained in the presence of high levels of 17α -hydroxyprogesterone. Basal cortisol levels were in the normal range for age. Similar results have been obtained in another child (4.2 years old), with gonadotropin-independent precocious puberty and tuberous sclerosis, who was also successfully treated for six months with ketoconazole (600 mg per day).⁷⁹ In three older children (5.0 to 7.4 years of age), an "escape" phenomenon occurred after one to three months of continuous treatment with 600 mg per day, probably because of the onset of puberty-like pituitary function. In these children, combined treatment with ketoconazole and a gonadotropin-releasing hormone analogue restored hormonal levels to the prepubertal range.⁸⁰ No signs of liver dysfunction or other side effects occurred in any child. In these preliminary studies, ketoconazole was a safe and effective inhibitor of testosterone overproduction in children. However, the long-term safety of high-dose treatment with the agent in children needs to be established.

Finally, because of its selective inhibition of androgen production at low doses,¹⁹ ketoconazole might be useful in the management of hirsutism. However, no clinical data on this issue are available at present, except for reports of a few patients who had regression of their hirsutism while receiving ketoconazole for Cushing's syndrome^{38,81} and one patient with hirsutism and polycystic ovary syndrome who had a striking improvement two months after starting ketoconazole therapy (200 mg twice daily).⁸² On the other hand, the effects on estrogen production are still controversial, and it is not known whether the drug affects hormonal cyclicity. Thus, the possible interference of ketoconazole with the human menstrual cycle should be evaluated.

INHIBITION OF CORTISOL PRODUCTION

When ketoconazole is administered to subjects with normal function of the hypothalamic-pituitary-adrenal axis, the plasma cortisol response to adrenocorticotropin is blunted for up to eight hours after a single dose of 400 or 600 mg.^{7,30,68,71,83} However, basal cortisol levels are not affected or are only slightly lower, even during long-term high-dose treatment

(up to 1200 mg per day).^{7,70,72,78} Signs of adrenal insufficiency are uncommon,^{58,67-69,71} probably because of a compensatory rise in adrenocorticotropin levels.^{3,70,72}

Therapeutic Use

Because ketoconazole is a potent inhibitor of cortisol production, through the inhibition of both adrenocortical 11β -hydroxylase and cholesterol side-chain cleavage (Fig. 2), it has been used in clinical trials of palliative treatment of Cushing's syndrome. Drug control of hypercortisolism is suitable for patients undergoing surgery, as well as for those treated with external pituitary radiation and those in whom more definitive treatment is delayed.⁸⁴

In patients with an adrenal tumor or pituitary-dependent Cushing's disease, plasma cortisol levels are suppressed and the cortisol response to adrenocorticotropin is blunted after administration of ketoconazole; inhibition of cortisol production by the drug has been confirmed in vitro in tissue slices of the excised tumors or hyperplastic adrenals.^{30,85,86} Beneficial endocrine effects of ketoconazole at doses ranging from 200 to 1000 mg per day have been observed in patients with Cushing's disease and in patients with either adrenal adenomas or carcinomas.⁸⁷ Increasing doses (from 400 to 1200 mg per day) have been used to reduce excess steroid effects in a patient with Cushing's syndrome secondary to a functioning adrenal tumor of the liver,²⁵ in a patient with primary adrenocortical micronodular adenomatosis,⁸⁸ and in one with Cushing's syndrome due to ectopic production of adrenocorticotropin by a small-cell lung cancer,⁸⁹ with improvement in clinical symptoms.

Since ketoconazole interferes with C_{17-20} lyase and is a more potent inhibitor of cholesterol side-chain cleavage activity, it can be expected that patients treated with the agent will be free of side effects such as mineralocorticoid excess or worsening of hirsutism, which may occur during treatment with metyrapone, which acts predominantly on 18α - and 11β -hydroxylases (Fig. 2). On the other hand, the antiandrogenic effects of ketoconazole may be disturbing in male patients. We used prolonged ketoconazole therapy (two to six months) in five patients with pituitary-dependent Cushing's disease and recurrent hypercortisolism after transsphenoidal surgery.⁸¹ A sixth patient was treated for two weeks before undergoing bilateral adrenalectomy. A dose of 400 mg every 12 hours was given during the first month and lowered thereafter, depending on individual responses. Urinary cortisol levels decreased to normal in all patients, and rapid clinical improvements were observed.⁸¹ No patient had signs of drug toxicity. Female patients had regression of hirsutism, whereas in the only male patient, who was treated for four months, gynecomastia developed. We are now treating additional patients with Cushing's disease with ketoconazole (600 mg per day). Drug doses necessary to maintain cortisol levels within the normal range in this condition are relatively

lower than those employed to suppress testosterone in prostatic cancer and are well tolerated.

Long-term administration of ketoconazole (3 to 13 months with 600 to 800 mg per day) in other groups of patients with pituitary-dependent Cushing's disease has also resulted in decreased cortisol levels and impressive clinical improvement,^{90,91} including regression of psychiatric symptoms.⁹⁰ It is noteworthy that unlike the findings in patients with an intact hypothalamic-pituitary-adrenal axis, there was no marked increase in adrenocorticotropin levels during long-term administration in any patient with Cushing's disease. Indeed, little change⁹¹ or a decrease⁹⁰ in plasma adrenocorticotropin concentrations was observed. In these patients, however, the adrenocorticotropin response to corticotropin-releasing hormone during administration of ketoconazole was unchanged⁹¹ or even enhanced⁹² as compared with the pretreatment response. This finding argues against an additional inhibitory effect at the pituitary level and is in agreement with the results of previous studies in animals.⁴³

Although no conclusions can be drawn from the data available, long-term treatment with adrenal inhibitors might modify the sensitivity of the hypothalamic-pituitary-adrenal axis in Cushing's disease, since unexpectedly low adrenocorticotropin levels have also been found during prolonged combined administration of metyrapone and aminoglutethimide.⁹³ One patient had marked regression of a functioning metastatic adrenal carcinoma while receiving palliative ketoconazole treatment. As in advanced prostate cancer,^{71,72,74} it is not known whether the drug acts on tumor cells by more than one mechanism.

OTHER EFFECTS

Cholesterol

Serum cholesterol levels were decreased after high-dose ketoconazole treatment in patients with advanced prostate cancer.^{72,94} The inhibition of cholesterol synthesis seems to be dose-dependent.⁹⁴ However, the effects of ketoconazole on cholesterol in humans need further evaluation with attention to potential benefits and harm, since the consequences of an accumulation of cholesterol precursors are not known.^{94,95}

Vitamin D

The inhibitory action of ketoconazole on kidney mitochondrial 24-hydroxylation of 25-hydroxyvitamin D^{14,27} has led to further investigation of the effect of this agent on 25-hydroxyvitamin D metabolism. In cultured chick kidney cells, ketoconazole and miconazole at therapeutic concentrations function as competitive inhibitors of both 1-hydroxylase and 24-hydroxylase activities.⁹⁶ These hydroxylases are also cytochrome P-450-dependent enzymes. After ketoconazole administration to normal volunteers, a dose-dependent reduction in serum 1,25-dihydroxyvitamin D levels with no change in serum levels of 25-hydroxyvitamin D and parathyroid hormone was observed.⁹⁷ It is not known whether the formation of

25-hydroxyvitamin D by a cytochrome P-450 enzyme in liver mitochondria is also impaired.

CONCLUSIONS

Recent research has extended the use of the antimycotic agent ketoconazole to endocrine conditions. Crucial factors modulating the drug's effects are the dosage and timing of administration. Relatively low and single daily doses are less likely to affect the endocrine system, whereas high or divided doses produce the maximum endocrine effects. As a potent testicular and adrenal steroid inhibitor with a predominant antiandrogenic action, ketoconazole is suitable for treatment of prostatic carcinoma, especially in combination with gonadotropin-releasing hormone analogues. The latter agents prevent the compensatory increase in luteinizing hormone and the consequent stimulation of testicular steroidogenesis that can overcome the enzyme blockade induced by ketoconazole. It should be pointed out that the available reports are still preliminary. International multicenter studies are in progress to define the role of high-dose ketoconazole in the treatment of prostatic cancer.⁹⁸ Further studies will show whether ketoconazole can be of value in the management of conditions of androgen excess, such as some forms of hirsutism and precocious puberty due to autonomous Leydig-cell hyperfunction.

In addition, ketoconazole has proved to be useful in treating Cushing's syndrome of various causes because of its ability to correct the severe complications of the disease quickly. Because of its differential selectivity, the drug can be used as an alternative to steroid inhibitors that produce side effects. Moreover, during prolonged treatment of pituitary-dependent Cushing's disease with ketoconazole, escape from adrenal inhibition does not seem to occur. However, the drug's interaction with the hypothalamic-pituitary-adrenal axis has not been fully clarified.

I am indebted to Dr. Alexander C. Brownie for his comments and suggestions and to Mrs. Esther Olczak for assistance in the preparation of the manuscript.

REFERENCES

1. Dixon D, Shadomy S, Shadomy HJ, Espinel-Ingraff A, Kerkerling TM. Comparison of the *in vitro* antifungal activities of miconazole and a new imidazole R41,400. *J Infect Dis* 1978; 138:245-8.
2. Thienpont D, Van Cutsem J, Van Gerven F, Heeres J, Janssen PAJ. Ketoconazole — a new broad spectrum orally active antimycotic. *Experientia* 1979; 35:606-7.
3. Graybill JR, Druiz DJ. Ketoconazole: a major innovation for treatment of fungal disease. *Ann Intern Med* 1980; 93:921-3.
4. DeFelice P, Johnson DG, Galgiani JN. Gynecoclasia with ketoconazole. *Antimicrob Agents Chemother* 1981; 19:1073-4.
5. Pont A, Williams PL, Azhar S, et al. Ketoconazole blocks testosterone synthesis. *Arch Intern Med* 1982; 142:2137-40.
6. Malozowski S, Mericq V, Cassoria F. Effects of ketoconazole on rat ovarian steroidogenic enzymatic activities. *Res Commun Chem Pathol Pharmacol* 1986; 52:403-6.
7. Pont A, Williams PL, Loose DS, et al. Ketoconazole blocks adrenal steroid synthesis. *Ann Intern Med* 1982; 97:370-2.
8. Pont A, Graybill JR, Craven PC, et al. High-dose ketoconazole therapy and adrenal and testicular function in humans. *Arch Intern Med* 1984; 144:2150-3.
9. DeCoster R, Caers I, Coene M-C, Amery W, Becrens D, Haetheman C. Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients. *Clin Endocrinol* 1986; 24:657-64.

10. Schürmeyer T, Nieschlag E. Effect of ketoconazole and other imidazole fungicides on testosterone biosynthesis. *Acta Endocrinol (Copenh)* 1984; 105:275-80.
11. Stevens DA. Ketoconazole metamorphosis: an antimicrobial becomes an endocrine drug. *Arch Intern Med* 1985; 145:813-5.
12. Van den Bossche H, Willemsens G, Cools W, Cornelissens F, Lauwers W, Van Cutsem J. *In vitro* and *in vivo* effects of the antimycotic drug ketoconazole on sterol synthesis. *Antimicrob Agents Chemother* 1980; 17:922-8.
13. Buttke TM, Chapman SW. Inhibition by ketoconazole of mitogen-induced DNA synthesis and cholesterol biosynthesis in lymphocytes. *Antimicrob Agents Chemother* 1983; 24:478-85.
14. Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. *J Clin Invest* 1983; 71:1495-9.
15. Mosca P, Bonazzi P, Novelli G, Jezequel AM, Orlandi F. *In vivo* and *in vitro* inhibition of hepatic microsomal drug metabolism by ketoconazole. *Br J Exp Pathol* 1985; 66:737-42.
16. Sheets JJ, Mason JJ. Ketoconazole: a potent inhibitor of cytochrome P-450-dependent drug metabolism in rat liver. *Drug Metab Dispos* 1984; 12:603-6.
17. Wilkinson CF, Metnarski K, Cantwell GP, Di Carlo FJ. Structure-activity relationships in the effects of 1-alkylimidazoles on microsomal oxidation *in vitro* and *in vivo*. *Biochem Pharmacol* 1974; 23:277-86.
18. Van den Bossche H, Lauwers W, Willemsens G, Cools W. Ketoconazole an inhibitor of the cytochrome P-450 dependent testosterone biosynthesis. *Prog Clin Biol Res* 1985; 185A:187-96.
19. Santen RJ, Van den Bossche H, Symoens J, Brugmans J, DeCoster R. Sites of action of low dose ketoconazole on androgen biosynthesis in men. *J Clin Endocrinol Metab* 1983; 57:732-6.
20. DeCoster R, Beerens D, Dom J, Willemsens G. Endocrinological effects of single daily ketoconazole administration in male beagle dogs. *Acta Endocrinol (Copenh)* 1984; 107:275-81.
21. Van den Bossche H, Lauwers W, Willemsens G, Cools W. The cytochrome P-450-dependent C₁₇₋₂₀ lyase in subcellular fractions of the rat testis: differences in sensitivity to ketoconazole and itraconazole. In: Boobis AR, Caldwell J, De Marcois F, Elcombe CR, eds. *Microsomes and drug oxidations*. London: Taylor and Francis, 1985:63-73.
22. Sikka SC, Swerdloff RS, Rajfer J. *In vitro* inhibition of testosterone biosynthesis by ketoconazole. *Endocrinology* 1985; 116:1920-5.
23. Rajfer J, Sikka SC, Rivera F, Handelsman DJ. Mechanism of inhibition of human testicular steroidogenesis by oral ketoconazole. *J Clin Endocrinol Metab* 1986; 63:1193-8.
24. Pont A, Trachtenberg J. Hormonal changes in patients on chronic high dose ketoconazole therapy. *Clin Res* 1984; 32:271A. abstract.
25. Contreras P, Altieri E, Liberman C, et al. Adrenal rest tumor of the liver causing Cushing's syndrome: treatment with ketoconazole preceding an apparent surgical cure. *J Clin Endocrinol Metab* 1985; 60:21-8.
26. Bhasin S, Sikka S, Fielder T, et al. Hormonal effects of ketoconazole *in vivo* in the male rat: mechanism of action. *Endocrinology* 1986; 118:1229-32.
27. Kan PB, Hirst MA, Feldman D. Inhibition of steroidogenic cytochrome P-450 enzymes in rat testis by ketoconazole and related imidazole antifungal drugs. *J Steroid Biochem* 1985; 23:1023-9.
28. Willemsens G, Van den Bossche H. Effects of ketoconazole on the testicular and adrenal cholesterol side-chain cleavage. In: Vereczky L, Magyar K, eds. *Cytochrome P-450, biochemistry, biophysics and induction*. Budapest: Akademiai Kiado, 1985:203-6.
29. Kowal J. The effect of ketoconazole on steroidogenesis in cultured mouse adrenal cortex tumor cells. *Endocrinology* 1983; 112:1541-3.
30. Engelhardt D, Dörr G, Jaspers C, Knorr D. Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 β -hydroxylase. *Klin Wochenschr* 1985; 63:607-12.
31. Nagai K, Miyamori I, Ikeda M, et al. Effect of ketoconazole (an imidazole antimycotic agent) and other inhibitors of steroidogenesis on cytochrome P450-catalyzed reactions. *J Steroid Biochem* 1986; 24:321-3.
32. Watanabe H, Menzies JA. Inhibition of ovarian aromatase by ketoconazole. *Res Commun Chem Pathol Pharmacol* 1986; 54:181-9.
33. Maloziowski S, Young I, Garcia H, Simoni C, Loriaux DL, Cassuria F. Effects of ketoconazole on rat testicular steroidogenic enzymatic activities. *Steroids* 1985; 46:659-63.
34. Ayub M, Stübgen SR. Effect of ketoconazole on placental aromatase, 3 β -hydroxysteroid dehydrogenase-isomerase and 17 β -hydroxysteroid dehydrogenase. *J Steroid Biochem* 1986; 25:981-4.
35. Pont A, Goldman ES, Sugar AM, Sileri PK, Stevens DA. Ketoconazole-induced increase in estradiol-testosterone ratio: probable explanation for gynecomastia. *Arch Intern Med* 1985; 145:1429-31.
36. DeCoster R, Caers I, Haelterman C, Debruyne M. Effect of a single administration of ketoconazole on total and physiologically free plasma testosterone and 17 β -oestradiol levels in healthy male volunteers. *Eur J Clin Pharmacol* 1985; 29:489-93.
37. Glass AR. Ketoconazole-induced stimulation of gonadotropin output in men: basis for a potential test of gonadotropin reserve. *J Clin Endocrinol Metab* 1986; 63:1121-5.
38. Contreras P, Rojas A, Biagini L, Gonzales P, Massardo T. Regression of metastatic adrenal carcinoma during palliative ketoconazole treatment. *Lancet* 1985; 2:151-2.
39. Vanden Bossche H, Willemsens G, Cools W, Bellens D. Molecular basis for ketoconazole's antifungal and anti-androgen activities. *J Steroid Biochem* 1985; 23:Suppl:36S. abstract.
40. Loose DS, Stover EP, Feldman D. Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. *J Clin Invest* 1983; 72:404-8.
41. Grosso DS, Boyden TW, Pamerier RW, Johnson DG, Stevens DA, Galgiani JN. Ketoconazole inhibition of testicular secretion of testosterone and displacement of steroid hormones from serum transport proteins. *Antimicrob Agents Chemother* 1983; 23:207-12.
42. Carlson HE. Gynecomastia. *N Engl J Med* 1980; 303:795-9.
43. Burrin JM, Yen TH, Ashby MJ, Bloom SR. Effect of ketoconazole on adrenocorticotrophic hormone secretion *in vitro* and *in vivo*. *J Endocrinol* 1986; 108:37-41.
44. Baxter JG, Brass C, Schentag JJ, Slaughter RL. Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. *J Pharm Sci* 1986; 75:443-7.
45. Shadomy S, Espinel-Ingroff A, Tartaglione TA, Dismukes WE. Treatment of systemic mycoses with ketoconazole: studies of ketoconazole serum levels. *Mykosen* 1986; 29:195-209.
46. Daneshmandi TK, Warnock DW, Turner A, Robert CJC. Pharmacokinetics of ketoconazole in normal subjects. *J Antimicrob Chemother* 1981; 8:299-304.
47. Heal RC, Bruggden RN, Carmine A, Morley PA, Speight TM, Avery GS. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. *Drugs* 1982; 23:1-36.
48. Van Tyle JH. Ketoconazole: mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. *Pharmacotherapy* 1984; 4:343-73.
49. Brass C, Galgiani JN, Blaschke TF, DeFelice R, O'Reilly RA, Stevens DA. Disposition of ketoconazole, an oral antifungal, in humans. *Antimicrob Agents Chemother* 1982; 21:151-8.
50. van der Meer JWM, Keuning JJ, Scheijgrond HW, Heykants J, Van Cutsem J, Brugmans J. The influence of gastric acidity on the bioavailability of ketoconazole. *J Antimicrob Chemother* 1980; 6:552-4.
51. Jorgensen JH, Alexander GA, Graybill JR, Drutz DJ. Sensitive bioassay for ketoconazole in serum and cerebrospinal fluid. *Antimicrob Agents Chemother* 1981; 20:59-62.
52. Turner CA, Turner A, Warnock DW. High performance liquid chromatographic determination of ketoconazole in human serum. *J Antimicrob Chemother* 1986; 18:757-63.
53. Sweczy SF, Giacomini KM, Abung A, Brass C, Stevens DA, Blaschke TF. Measurement of ketoconazole, a new antifungal agent, by high-performance liquid chromatography. *J Chromatogr* 1982; 277:510-5.
54. Borelli D, Bran JL, Fuentes J, et al. Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs. *Postgrad Med J* 1979; 55:657-61.
55. Craven PC, Graybill JR, Jorgensen JH, Dismukes WE, Levine BE. High-dose ketoconazole for treatment of fungal infections of the central nervous system. *Ann Intern Med* 1983; 98:160-7.
56. Brown MW, Maldonado AL, Meredith CG, Speeg KV Jr. Effect of ketoconazole on hepatic oxidative drug metabolism. *Clin Pharmacol Ther* 1985; 37:290-7.
57. Smith AG. Potentiation of oral anticoagulants by ketoconazole. *Br Med J* 1984; 288:188-9.
58. Engelhard D, Stutman HR, Marks MI. Interaction of ketoconazole with rifampin and isoniazid. *N Engl J Med* 1984; 311:1681-3.
59. Glynn AM, Slaughter BE, Brass C, d'Ambrosio R, Jusko WJ. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. *Clin Pharmacol Ther* 1986; 39:654-9.
60. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy: analysis of 33 cases. *Gastroenterology* 1984; 86:503-13.
61. Lake-Bakaar G, Scheuer PJ, Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. *Br Med J* 1987; 294:419-22.
62. McCance DR, Ritchie CM, Sheridan B, Atkinson AB. Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole. *Lancet* 1987; 1:573.
63. Macnair AJ, Gascoigne E, Heap J, Schuurmans V, Symoens J. Hepatitis and ketoconazole therapy. *Br Med J* 1981; 283:1058.
64. Duarte PA, Chow CC, Simmons F, Ruskin J. Fatal hepatitis associated with ketoconazole therapy. *Arch Intern Med* 1984; 144:1069-70.
65. van Dijke CPH, Voerman FR, Haverkamp HC. Anaphylactic reactions to ketoconazole. *Br Med J* 1983; 287:1673.
66. Vawda AI, Davies AG. An investigation into the effects of ketoconazole on testicular function in Wistar rats. *Acta Endocrinol (Copenh)* 1986; 111:246-51.
67. Tucker WS Jr, Snell BB, Island DP, Gregg CW. Reversible adrenal insufficiency induced by ketoconazole. *JAMA* 1985; 253:2413-4.
68. White MC, Kendall-Taylor P. Adrenal hypofunction in patients taking ketoconazole. *Lancet* 1985; 1:44-5.

69. Pillans PI, Cowan P, Whitelaw D. Hyponatremia and confusion in a patient taking ketoconazole. *Lancet* 1985; 1:821-2.
70. Heyns W, Drochmans A, van der Schueren E, Verhoeven G. Endocrine effects of high-dose ketoconazole therapy in advanced prostatic cancer. *Acta Endocrinol (Copenh)* 1985; 110:276-83.
71. Denis L, Chaban M, Mahler C. Clinical applications of ketoconazole in prostatic cancer. *Prog Clin Biol Res* 1985; 185A:319-26.
72. Trachtenberg J, Pont A. Ketoconazole therapy for advanced prostate cancer. *Lancet* 1984; 2:433-5.
73. Trachtenberg J, Halpern N, Pont A. Ketoconazole: a novel and rapid treatment for advanced prostatic cancer. *J Urol* 1983; 130:152-3.
74. Trachtenberg J. Ketoconazole therapy in advanced prostatic cancer. *J Urol* 1984; 132:61-3.
75. Williams G. Ketoconazole for prostate cancer. *Lancet* 1984; 2:696.
76. Allen JM, Kerle DJ, Ware H, Dobie A, Williams G, Bloom S. Combined treatment with ketoconazole and luteinizing hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer. *Br Med J* 1983; 287:1766.
77. English HF, Santner SJ, Levine MB, Santen RJ. Inhibition of testosterone production with ketoconazole alone and in combination with a gonadotropin releasing hormone analogue in the rat. *Cancer Res* 1986; 46:38-42.
78. Holland FJ, Fishman L, Bailey JD, Fazekas ATA. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy. *N Engl J Med* 1985; 312:1023-8.
79. Root AW, Zamanillo J, Duckett G, Sweetland M. Gonadotropin-independent isosexual precocity in a boy with tuberous sclerosis: effect of ketoconazole. *J Pediatr* 1986; 109:1012-5.
80. Holland FJ, Kirsch SE, Selby R. Gonadotropin-independent precocious puberty ("testotoxicosis"): influence of maturational status on response to ketoconazole. *J Clin Endocrinol Metab* 1987; 64:328-33.
81. Sonino N, Boscaro M, Merola G, Mantero F. Prolonged treatment of Cushing's disease by ketoconazole. *J Clin Endocrinol Metab* 1985; 61:718-22.
82. Carvalho D, Pignatelli D, Resende C. Ketoconazole for hirsutism. *Lancet* 1985; 2:560.
83. Bradbrook ID, Gillies HC, Morrison PJ, Robinson J, Rogers HJ, Spector RG. Effects of single and multiple doses of ketoconazole on adrenal function in normal subjects. *Br J Clin Pharmacol* 1985; 20:163-5.
84. Sonino N, Merola G. The use of steroid inhibitors in the management of patients. In: Agarwal MK, ed. *Adrenal steroid antagonism*. Berlin: Walter de Gruyter, 1984:341-69.
85. Engelhardt D, Mann K, Hörmann R, Braun S, Karl HJ. Ketoconazole inhibits cortisol secretion of an adrenal adenoma *in vivo* and *in vitro*. *Klin Wochenschr* 1983; 61:373-5.
86. Engelhardt D, Mann K, Hörmann R, Jüngst D, Braun S, Karl HJ. The influence of ketoconazole on cortisol secretion in Cushing's syndrome: *in vivo* and *in vitro* studies of six patients. *Acta Endocrinol (Suppl)* (Copenh) 1983; 256:281, abstract.
87. Contreurs P, Rojas A, Costamailere L, Michelsen H, Pumarino H, Artcaga E. Endocrine effects of ketoconazole administration in 10 patients with Cushing's syndrome. In: Program and Abstracts of the 67th Annual Meeting of the Endocrine Society, Baltimore, 1985:138, abstract.
88. Oelkers W, Bähr V, Hensen J, Pickartz H. Primary adrenocortical micro-nodular adenomatosis causing Cushing's syndrome: effects of ketoconazole on steroid production and *in vitro* performance of adrenal cells. *Acta Endocrinol (Copenh)* 1986; 113:370-7.
89. Shepherd FA, Moffert B, Evans WK, Emery G, Trachtenberg J. Ketoconazole: use in the treatment of ectopic adrenocorticotrophic hormone production and Cushing's syndrome in small-cell lung cancer. *Arch Intern Med* 1985; 145:863-4.
90. Angeli A, Frattini R. Ketoconazole therapy in Cushing's disease. *Lancet* 1985; 1:821.
91. Loli P, Berselli ME, Tagliaferri M. Use of ketoconazole in the treatment of Cushing's syndrome. *J Clin Endocrinol Metab* 1986; 63:1365-71.
92. Boscaro M, Sonino N, Rampazzo A, Mantero F. Response of pituitary adrenal axis to corticotropin releasing hormone in patients with Cushing's disease before and after ketoconazole treatment. *Clin Endocrinol (in press)*.
93. Sonino N, Boscaro M, Ambrosio G, Merola G, Mantero F. Prolonged treatment of Cushing's disease by metyrapone and aminogluethimide. *IRCS J Med Sci* 1986; 14:485-6.
94. Kraemer FB, Pont A. Inhibition of cholesterol synthesis by ketoconazole. *Am J Med* 1986; 80:616-22.
95. Miettinen TA, Valtonen VV. Ketoconazole and cholesterol synthesis. *Lancet* 1984; 2:1271.
96. Henry HL. Effect of ketoconazole and miconazole on 25-hydroxyvitamin D₃ metabolism by cultured chick kidney cells. *J Steroid Biochem* 1985; 23:991-4.
97. Glass AR, Eil C. Ketoconazole-induced reduction in serum 1,25-dihydroxy-vitamin D. *J Clin Endocrinol Metab* 1986; 63:766-9.
98. Van den Bossche H, DeCoster R, Amery WK. Pharmacology and clinical uses of ketoconazole. In: Furr BJA, Wakeling AE, eds. *Pharmacology and clinical uses of inhibitors of hormone secretion and action*. London: Baillière-Tindall, 1987:288-307.

Massachusetts Medical Society
Registry on Continuing Medical Education

To obtain information on continuing medical education courses in the New England area, write or call, indicating field(s) or specialty in which information is desired, the Committee on Medical Education, 1440 Main St., Waltham, MA 02254; telephone (617) 893-4610 (Metropolitan Boston) or WATS 1-800-322-2303 (Massachusetts).